Hide and Seq combines predictive and prognostic biomarkers to promote effective treatment for several types of cancer. The company is developing an in vitro diagnostic genomic signature that identifies which patients should be offered an alternative chemotherapy in first and second lines of treatment.

Hide and Seq is developing a predictive assay for first-line therapy aimed at identifying chemotherapy resistance to paclitaxel (Taxol) in patients with metastatic ovarian cancer. A predictive genetic assay will offer physicians a personally tailored mode of treatment intended to increase treatment efficacy and survival.